TOVX
Theriva Biologics, Inc.
Key Financials
Operating Income
$-24051000
↑ 8.7%
Revenue
$300000
N/A
Total Assets
$38.2M
↑ 8.2%
EPS (Diluted)
$-2.08
↑ 89.1%
Total Liabilities
$22.9M
↑ 40.4%
Net Income
$-18349000
↑ 6.8%
Cash & Equivalents
$13.1M
↑ 12.5%
Shareholders' Equity
$56.4M
↓ 9.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| DEF 14A | 6/29/2026 | View on SEC |
| ARS | 6/29/2026 | View on SEC |
| PRE 14A | 6/18/2026 | View on SEC |
| 8-K | 6/11/2026 | View on SEC |
| 8-K | 6/5/2026 | View on SEC |
| 10-Q | 5/5/2026 | View on SEC |
| 8-K | 5/5/2026 | View on SEC |
| DEF 14A | 4/30/2026 | View on SEC |
| PRE 14A | 4/20/2026 | View on SEC |
| 8-K | 4/17/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TOVX |
| Company Name | Theriva Biologics, Inc. |
| CIK | 894158 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NV |
| Phone | (734) 332-7800 |